

United States of America

United States Patent and Trademark Office

Neuracthel

Reg. No. 7,265,343

Registered Jan. 09, 2024

Corrected Jul. 30, 2024

Int. Cl.: 3, 5, 10

Trademark

Principal Register

Clinuvel Europe Ltd (IRELAND Limited company)
Earlsfort Terrace 10
Dublin 2 D02 T380
IRELAND

CLASS 3: Non-medicated cosmetics; cosmetics for protecting against light and UV; cosmetics, namely, cosmetic products as leave-on, lotions, creams, ointments and other formulations as well as cosmetic products for topical use; non-medicated *skin care* preparations for protecting the skin against light and UV; non-medicated skin *care* photoprotection preparations; *non-medicated* sun care preparations for cosmetic use; sun-tanning preparations; *cosmetic* suntan lotions; suntan oils *for cosmetic purposes;* tanning gels; cosmetic preparations for skin care containing analogues of melanocyte stimulating hormone (MSH), in particular afamelanotide; cosmetics for tanning the skin containing analogues of melanocyte stimulating hormone (MSH), in particular afamelanotide; cosmetic preparations for tanning the skin without sunlight containing analogues of melanocyte stimulating hormone (MSH), in particular afamelanotide; sun screen preparations; cosmetic preparations for protecting the skin from the sun's rays; cosmetics for protecting the skin from sunburn; sun protecting creams; sun *block preparations;* sun block; sun blocking preparations; sun-block lotions; sun blocking oils; SPF sun block sprays; *lip balm with sun block;* sun blocking lipsticks; *cosmetic sunscreen preparations;* waterproof sunscreen *preparations;* water-resistant sunscreen *preparations;* sunscreen preparations; sunscreen creams; sunscreen lotions; sunscreen sticks; cosmetic foams containing sunscreen *preparations; sunscreen* preparations for protecting the hair from the sun; *nonmedicated cosmetic preparations against sunburns;* non-medicated *sun care preparations* for skin care after exposure to the sun's rays

CLASS 5: Pharmaceuticals *for the prevention and treatment of neurological, endocrinological, and degenerative disorders;* pharmaceutical drugs *for the prevention and treatment of epidermal problems, and damaged skin and tissue;* pharmaceutical products for endocrine, neuroendocrine, systemic, inflammatory, and acute disorders such as sepsis, shock, haemorrhagic shock, acute bleeding disorders, and chronic disorders requiring prevention, curative or palliative treatment where no other treatments are effective or safe; pharmaceutical preparations *for the prevention and treatment of viral, metabolic, genetic, endocrine, musculoskeletal, ophthalmic, cardiovascular, cerebrovascular, cardiopulmonary, genitourinary, oncological, hepatological, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric, and immune system related diseases and disorders;* pharmaceuticals used for cerebrovascular accidents *in the nature of strokes*; pharmaceutical preparations for the prevention and treatment of arterial ischemic strokes; medicines for the treatment of cardiovascular and cerebrovascular diseases; pharmaceutical preparations for the prevention and treatment of cardiovascular and cerebrovascular diseases; cardiovascular drugs for use in treating hypertension; cardiovascular preparations *for the prevention and treatment of cardiometabolic conditions;* cardiovascular pharmaceuticals *for the prevention and treatment of ischemic syndromes;* cardiovascular pharmaceutical

Katherine Kelly Vidal

Director of the United States
Patent and Trademark Office



preparations *for the prevention and treatment of cardiomyopathies;* cardiovascular agents for medical purposes; cardiovascular drugs used in treating *cardiogenic shocks;* cardiovascular drugs used in myocardial infarctions; cardiovascular drugs used in treating arrhythmias; cardiovascular drugs used in angina pectoris; cardiovascular drugs used in treating congestive heart failure (CHF); pharmaceutical preparations containing analogues of melanocyte stimulating hormone (MSH), in particular afamelanotide; medicated sun care preparations, namely, sun tanning preparations for pharmaceutical purposes containing analogues of melanocyte stimulating hormone (MSH), in particular afamelanotide; pharmaceutical preparations for skin care; pharmaceutical preparations for treating skin disorders; *dermatologicals, namely, dermatological preparations, dermatological pharmaceutical substances, dermatological pharmaceutical products;* medicinal creams for the protection of the skin; skin care creams for medical use; skin care preparations for medical use; medicated skin creams and lotions; medicated *skin care* creams for application after exposure to the sun; pharmaceutical skin lotions; preparations for cleansing the skin for medical use; *medicated chemical and biological skin care preparations and chemical reagents* for medical purposes which contain analogues of melanocyte stimulating hormone (MSH), in particular afamelanotide; *drug afamelanotide in aqueous and gel formulations;* pharmaceutical implants *comprising living tissue;* subcutaneous implants containing *living tissue and also containing* afamelanotide; implantable *subcutaneous drug delivery devices sold filled with pharmaceutical preparations for the prevention and treatment of neurological, endocrinological, and degenerative disorders; implantable subcutaneous drug delivery devices sold filled with pharmaceutical preparations and containing afamelanotide for the prevention and treatment of skin related diseases and disorder*

CLASS 10: Medical apparatus, devices and instruments *for accessing subcutaneous structures of the human body for the purpose of administering medical treatment;* apparatus for drug administration, *namely, drug delivery catheters;* devices for use in the administration of pharmaceuticals, namely, implantable drug delivery ports; controlled rate release apparatus for dispensing pharmaceutical substances, *namely, implantable drug delivery pumps;* medical fluid injectors; injection syringes; medical syringes; implantable subcutaneous drug delivery *ports and pumps*

THE MARK CONSISTS OF STANDARD CHARACTERS WITHOUT CLAIM TO ANY PARTICULAR FONT STYLE, SIZE OR COLOR

PRIORITY DATE OF 10-18-2021 IS CLAIMED

OWNER OF INTERNATIONAL REGISTRATION 1681470 DATED 04-07-2022, EXPIRES 04-07-2032

SER. NO. 79-348,994, FILED 04-07-2022

REQUIREMENTS TO MAINTAIN YOUR FEDERAL TRADEMARK REGISTRATION

WARNING: YOUR REGISTRATION WILL BE CANCELLED IF YOU DO NOT FILE THE DOCUMENTS BELOW DURING THE SPECIFIED TIME PERIODS.

Requirements in the First Ten Years*

What and When to File:

- **First Filing Deadline:** You must file a Declaration of Use (or Excusable Nonuse) between the 5th and 6th years after the registration date. See 15 U.S.C. §§1058, 1141k. If the declaration is accepted, the registration will continue in force for the remainder of the ten-year period, calculated from the registration date, unless cancelled by an order of the Commissioner for Trademarks or a federal court.
- **Second Filing Deadline:** You must file a Declaration of Use (or Excusable Nonuse) and an Application for Renewal between the 9th and 10th years after the registration date.* See 15 U.S.C. §1059.

Requirements in Successive Ten-Year Periods*

What and When to File:

- You must file a Declaration of Use (or Excusable Nonuse) and an Application for Renewal between every 9th and 10th-year period, calculated from the registration date.*

Grace Period Filings*

The above documents will be accepted as timely if filed within six months after the deadlines listed above with the payment of an additional fee.

***ATTENTION MADRID PROTOCOL REGISTRANTS:** The holder of an international registration with an extension of protection to the United States under the Madrid Protocol must timely file the Declarations of Use (or Excusable Nonuse) referenced above directly with the United States Patent and Trademark Office (USPTO). The time periods for filing are based on the U.S. registration date (not the international registration date). The deadlines and grace periods for the Declarations of Use (or Excusable Nonuse) are identical to those for nationally issued registrations. See 15 U.S.C. §§1058, 1141k. However, owners of international registrations do not file renewal applications at the USPTO. Instead, the holder must file a renewal of the underlying international registration at the International Bureau of the World Intellectual Property Organization, under Article 7 of the Madrid Protocol, before the expiration of each ten-year term of protection, calculated from the date of the international registration. See 15 U.S.C. §1141j. For more information and renewal forms for the international registration, see <http://www.wipo.int/madrid/en/>.

NOTE: Fees and requirements for maintaining registrations are subject to change. Please check the USPTO website for further information. With the exception of renewal applications for registered extensions of protection, you can file the registration maintenance documents referenced above online at <http://www.uspto.gov>.

NOTE: A courtesy e-mail reminder of USPTO maintenance filing deadlines will be sent to trademark owners/holders who authorize e-mail communication and maintain a current e-mail address with the USPTO. To ensure that e-mail is authorized and your address is current, please use the Trademark Electronic Application System (TEAS) Correspondence Address and Change of Owner Address Forms available at <http://www.uspto.gov>.